News
Market and company headlines
Clorox (CLX) is back in focus after management kept its dividend in place despite a payout ratio around 149% of free cash flow and leadership transition plans for CEO Linda Rendle. Recent trading tells a mixed story. Clorox shares are up 3.31% over the past week but down 10.51% over 90 days, and the 1 year total shareholder return has declined 23.28%. This suggests that short term momentum has picked up while longer term returns remain under pressure as investors reassess dividend risk and...

Clorox has seen its share price fall over several time frames, which puts fresh attention on what investors are actually paying for its earnings today. With the stock under pressure, the key issue is whether the current valuation lines up with the profits the business is generating. Over the past 5 years the share price has declined 37.1%, which puts longer term holders squarely focused on whether the earnings now justify staying invested. As a mature household products business that depends...
Clorox is set to report its Q1 results next month, with analysts projecting strong double-digit year-over-year EPS growth.

Morgan Stanley analyst Dara Mohsenian maintains Clorox (NYSE:CLX) with a Equal-Weight and lowers the price target from $97 to $87.

Key TakeawaysAltria and Clorox both yielded just over 6% at the Oct. 9, 2026 close: 6.

Key TakeawaysCampbell’s cut its quarterly dividend 36% to $0. 25 a share on Sept.

Citigroup analyst Filippo Falorni maintains Clorox (NYSE:CLX) with a Neutral and lowers the price target from $97 to $90.
Palm Valley Capital Management, an investment management firm, has issued the third-quarter 2026 investor letter for the “Palm Valley Capital Fund.” The letter can be downloaded here. During the quarter, the Palm Valley Capital Fund gained 1.61%, while the S&P SmallCap 600 Index fell 7.93% and the Morningstar Small Cap Total Return Index decreased by […]

Wells Fargo analyst Chris Carey maintains Clorox (NYSE:CLX) with a Equal-Weight and lowers the price target from $90 to $85.

Consumer staples aren't looking so safe anymore. Here's why Clorox and General Mills are struggling, and why I think Constellation Brands may be better positioned for a higher-rate world.

The Clorox Company (NYSE:CLX) is the kind of company that’s easy to recognize. You probably don’t have to think too hard to come up with one of its products. Clorox bleach, Glad bags, Hidden Valley dressing, Brita filters, Burt’s Bees, and Fresh Step are all familiar names. That familiarity is a big part of what […]

CLX's innovation, GOJO acquisition and digital transformation are strengthening its health and hygiene portfolio while supporting long-term growth.

Investors need to pay close attention to CLX stock based on the movements in the options market lately.

Clorox (CLX) has put its latest acquisition to work, launching the Clorox Purell ProCare health and hygiene platform. The new platform combines CloroxPro with GOJO under a unified offering for professional and healthcare customers. For investors, the Clorox Purell ProCare launch lands at a tricky moment. The share price closed at US$83.80, with a 1-day share price return of 2.44% that sits against a 30-day share price decline of 18.27% and a 1-year total shareholder return that is down...

The Clorox Company today announced the launch of Clorox Purell ProCare™, an industry-leading health and hygiene platform combining CloroxPro and GOJO, Makers of Purell, which Clorox acquired earlier this year. Clorox Purell ProCare's unified sales and service organization and network of leading distributors offer professional and healthcare customers convenient access to its broad portfolio of innovative solutions from trusted brands like Clorox, Purell, Pine-Sol, Glad and more.
Clorox looks more attractive as ERP issues fade; GOJO adds growth and guidance improves. Read here for a detailed investment analysis of CLX stock.

The Clorox Company is down 21% in a month. Itâs rated a Sell: falling organic sales, margin erosion, weak catalysts, and valuation risks. Click for a CLX update.

The Clorox Company (NYSE: CLX) announced today that its board of directors has declared a quarterly dividend of $1.25 per share on the company's common stock. The dividend is payable November 13, 2026, to shareholders of record as of the close of business on October 28, 2026.

Clorox has underperformed the consumer staples sector over the past three months. Wall Street analysts are tepid about its prospects.

PG faces a $1.4 billion after-tax earnings headwind in fiscal 2027 as rising costs, FX pressure and other factors weigh on margins.
Both Clorox and Kimberly-Clark have raised their dividends for years and offer yields above 5%, but one of them is sitting on a payout that its own management quietly admits may not be sustainable.

When quality dividend stocks drift toward 52-week lows, patient income investors often find their best opportunities hiding in plain sight. Five household names are sitting at beaten-down prices right now, and the yields they are offering demand a closer look.
The Clorox Company (CLX) Barclays 19th Annual Global Consumer Staples Conference September 9, 2026 9:00 AM EDTCompany ParticipantsLinda Rendle - CEO &...

CLX is using cost savings, ERP optimization and pricing to cushion inflation, but the FY27 gross margin is still projected at 42%.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
CLX's GOJO deal boosts fiscal 2027 sales, but inflation, acquisition costs and margin pressure could limit underlying growth.

CLX's GOJO-led growth faces margin pressure, muted core demand and inflation risks, leaving investors focused on a durable recovery.

CLX's rebound faces margin pressure, muted underlying demand and weaker earnings revisions despite GOJO and ERP tailwinds.
CL raised its 2026 profit outlook after a Q2 earnings beat and 140-basis-point margin gain, while higher costs and North America remain risks.
CL enters the second half with better volumes, resilient margins and a higher earnings outlook, but rich valuation and U.S. weakness temper the upside.
As Clorox has underperformed the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

ENR trades at a steep discount, but weak earnings, margin pressure and soft battery demand challenge the case for a rebound.
Clorox’s second quarter generated a positive response from investors, as revenue surpassed analyst expectations despite a 2% year-over-year decline. Management attributed the quarter’s performance to targeted improvements in product superiority, focused brand investments, and effective promotional execution in key categories. CEO Linda Rendle noted that, “the majority of our businesses are performing at or above expectations,” while acknowledging operational challenges in segments like Litter an

GOJO acquisition boosts health segment as organic sales decline amid inflation headwinds.




